National Bank of Canada
PCVX icon

National Bank of Canada’s Vaxcyte PCVX Stock Holding History

National Bank of Canada’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13
Closed -$468 – 3067
2025
Q3 		$468 Buy
+13
New +$431 ﹤0.01% 2697
2025
Q2 		– Sell
-494
Closed -$18.7K – 3173
2025
Q1 		$18.7K Sell
494
-6
-1% -$480 ﹤0.01% 2104
2024
Q4 		$41K Buy
+500
New +$49.6K ﹤0.01% 2007
2023
Q1 		– Sell
-485,538
Closed -$23.3M – 2823
2022
Q4 		$23.3M Sell
485,538
-400,000
-45% -$15.7M 0.06% 256
2022
Q3 		$21.3M Buy
+885,538
New +$22.4M 0.11% 200

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

National Bank of Canada's PCVX Position: Q4 2025 in Review

National Bank of Canada sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 13 shares — an estimated $468 sold.

National Bank of Canada first reported a position in PCVX in Q3 2022 and held it in 5 quarters. The position peaked at $23.3M in Q4 2022. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • National Bank of Canada reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • National Bank of Canada sold 13 Vaxcyte shares in Q4 2025, an estimated $468.
  • National Bank of Canada first reported a position in Vaxcyte in Q3 2022 and held it in 5 quarters.
  • National Bank of Canada's Vaxcyte position peaked at $23.3M in Q4 2022.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.